Stock Events

Stock Events

Verrica Pharmaceuticals 

€4.56
30
+€0.13+2.82% Thursday 06:03

Statistics

Day High
4.56
Day Low
4.56
52W High
7.4
52W Low
2.94
Volume
-
Avg. Volume
-
Mkt Cap
78.25M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

9NovExpected
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-1.13
-0.75
-0.36
0.02
Expected EPS
-0.42788068399999996
Actual EPS
N/A

Financials

-52.26%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
30.52MRevenue
-15.95MNet Income

Analyst Ratings

9.11Average Price Target
The highest estimate is 9.11.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 1NE0.F. It's not an investment recommendation.
AMD
6
AMD
Apple
5
AAPL
Realty Income
4
O
Amazon
4
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AnaptysBio
ANAB
Mkt Cap1.67B
AnaptysBio, Inc. focuses on developing antibody-based therapies for dermatological conditions, directly competing with Verrica's dermatology products.
Journey Medical
DERM
Mkt Cap210.84M
Journey Medical Corporation is directly involved in dermatology, marketing products that compete in the same space as Verrica's treatments for skin conditions.
Bausch Health Companies
BHC
Mkt Cap2.36B
Bausch Health Companies Inc. has a broad portfolio in dermatology, offering products that compete with Verrica's skin treatment solutions.
Pfizer
PFE
Mkt Cap159.36B
Pfizer Inc. has a diverse range of healthcare products, including treatments for dermatological conditions, making it a competitor in the dermatology market.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson, through its Janssen Pharmaceuticals segment, offers products for skin health, competing in the same market as Verrica.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie Inc. has a strong presence in dermatology with its Humira product and others, competing in the same therapeutic areas as Verrica.
AMGEN
AMGN
Mkt Cap233.78B
Amgen Inc. develops treatments for various conditions, including skin diseases, making it a competitor in the dermatology space.
GSK
GSK
Mkt Cap101.78B
GlaxoSmithKline plc has a portfolio that includes treatments for skin conditions, competing with Verrica's dermatological products.
Merck
MRK
Mkt Cap366B
Merck & Co., Inc. offers a range of healthcare products, including treatments for skin conditions, making it a competitor in the dermatology market.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals, Inc. is known for its innovative treatments in dermatology, directly competing with Verrica Pharmaceuticals in the development of skin disease treatments.

About

Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.
Show more...
CEO
Jayson Rieger
Employees
76
Country
United States
ISIN
US92511W2070
WKN
000A41A98

Listings

XNAS
US
VRCA
STU
DE
1NE0.STU
STU
DE
1NE.STU
MU
DE
1NE0.MU

0 Comments

Share your thoughts

FAQ

What is Verrica Pharmaceuticals stock price today?▼
The current price of 1NE0.F is €4.56 EUR — it has increased by +2.82% in the past 24 hours. Watch Verrica Pharmaceuticals stock price performance more closely on the chart.
What is Verrica Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Frankfurt Exchange exchange Verrica Pharmaceuticals stocks are traded under the ticker 1NE0.F.
What is Verrica Pharmaceuticals market cap?▼
Today Verrica Pharmaceuticals has the market capitalization of 78.25M
When is the next Verrica Pharmaceuticals earnings date?▼
Verrica Pharmaceuticals is going to release the next earnings report on November 09, 2026.
What were Verrica Pharmaceuticals earnings last quarter?▼
1NE0.F earnings for the last quarter are -0.54 EUR per share, whereas the estimation was -0.34 EUR resulting in a -60% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Verrica Pharmaceuticals revenue for the last year?▼
Verrica Pharmaceuticals revenue for the last year amounts to 30.52M EUR.
What is Verrica Pharmaceuticals net income for the last year?▼
1NE0.F net income for the last year is -15.95M EUR.
How many employees does Verrica Pharmaceuticals have?▼
As of September 04, 2026, the company has 76 employees.
In which sector is Verrica Pharmaceuticals located?▼
Verrica Pharmaceuticals operates in the Health & Wellness sector.
When did Verrica Pharmaceuticals complete a stock split?▼
The last stock split for Verrica Pharmaceuticals was on July 25, 2025 with a ratio of 1:10.
Where is Verrica Pharmaceuticals headquartered?▼
Verrica Pharmaceuticals is headquartered in WEST CHESTER, United States.